Intestinal microbiota in colorectalcancer

Recruiting

• Conditions: Intestinal microbiota, microbiome, Colorectal cancer treatment, chemotoxicity, responsIntestinale microbiota, microbioom, colorectaal carcinoom behandeling, chemotoxiciteit, respons

• Registration Number: NL-OMON29314
• Lead Sponsor: AZM

Brief Summary

Aarnoutse, R., de Vos-Geelen, J. M. P. G. M., Penders, J., Boerma, E. G., Warmerdam, F. A. R. M., Goorts, B., Olde Damink, S. W. M., Soons, Z., Rensen, S. S. M., and Smidt, M. L. (2017) Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0, International Journal of Colorectal Disease, 1-8.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 66

Inclusion Criteria

• Patients diagnosed with metastatic and/or irresectable CRC who will be treated with oral capecitabine (with or without intravenous bevacizumab) or oral trifluridine/tipiracil (TAS-102).

• Aged 18 years or older.

Exclusion Criteria

• Proven Microsatellite instability (MSI).

• Has not received any prior systemic therapy for the treatment of CRC during the previous 4 weeks prior to start of the current line of capecitabine or TAS-102.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Microbiota composition before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity

Secondary Outcome Measures

Name	Time	Method
Absolute microbiota abundance before, during and after 3 cycles systemic treatment with capecitabine or TAS-102 related to respons & chemotoxicity